Evidence map›Paper›PMID 38491495›Full record

ReviewVirology journal2024

Liver injury in COVID-19: an insight into pathobiology and roles of risk factors.

Abbas Tazarghi, Sahar Bazoq, Mohammad Hosein Taziki Balajelini, Mohsen Ebrahimi, Seyed Mehran Hosseini, Hadi Razavi Nikoo

Open access · goldAbstract readReview
In one paragraph

Review in Virology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. COVID-19 Infection, Drugs, and Liver Injury.Journal of clinical medicine · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Abbas Tazarghi *Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Sahar Bazoq *Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Mohammad Hosein Taziki BalajeliniDepartment of Otorhinolaryngology, Neuroscience Research Center, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Mohsen EbrahimiNeonatal and Children's Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Seyed Mehran HosseiniDepartment of Physiology, School of Medicine, Neuroscience Research Center, Golestan University of Medical Sciences, Gorgan, Iran. hosseini@goums.ac.ir.
Hadi Razavi NikooDepartment of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran. Hadirazavi96@gmail.com.
Golestan University of Medical Sciences · IRGolestan University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is a complex disease that can lead to fatal respiratory failure with extrapulmonary complications, either as a direct result of viral invasion in multiple organs or secondary to oxygen supply shortage. Liver is susceptible to many viral pathogens, and due to its versatile functions in the body, it is of great interest to determine how hepatocytes may interact with SARS-CoV-2 in COVID-19 patients. Liver injury is a major cause of death, and SARS-CoV-2 is suspected to contribute significantly to hepatopathy. Owing to the lack of knowledge in this field, further research is required to address these ambiguities. Therefore, we aimed to provide a comprehensive insight into host-virus interactions, underlying mechanisms, and associated risk factors by collecting results from epidemiological analyses and relevant laboratory experiments. Backed by an avalanche of recent studies, our findings support that liver injury is a sequela of severe COVID-19, and certain pre-existing liver conditions can also intensify the morbidity of SARS-CoV-2 infection in synergy. Notably, age, sex, lifestyle, dietary habits, coinfection, and particular drug regimens play a decisive role in the final outcome and prognosis as well. Taken together, our goal was to unravel these complexities concerning the development of novel diagnostic, prophylactic, and therapeutic approaches with a focus on prioritizing high-risk groups.

Indexed as

COVID-19Liver DiseasesHumansRisk FactorsSARS-CoV-2COVID-19Liver injuryPathobiology mechanismsRisk factorsSARS-CoV-2

Identifiers

PMID38491495
PMCPMC10943793
OpenAlexW4392861979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.